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Abstract
Purpose To explore whether high intake of cod or salmon would affect gut microbiota profile, faecal output and serum 
concentrations of lipids and bile acids.
Methods Seventy-six adults with overweight/obesity with no reported gastrointestinal disease were randomly assigned to 
consume 750 g/week of either cod or salmon, or to avoid fish intake (Control group) for 8 weeks. Fifteen participants from 
each group were randomly selected for 72 h faeces collection at baseline and end point for gut microbiota profile analyses 
using 54 bacterial DNA probes. Food intake was registered, and fasting serum and morning urine were collected at baseline 
and end point.
Results Sixty-five participants were included in serum and urine analyses, and gut microbiota profile was analysed for 33 
participants. Principal component analysis of gut microbiota showed an almost complete separation of the Salmon group from 
the Control group, with lower counts for bacteria in the Bacteroidetes phylum and the Clostridiales order of the Firmicutes 
phyla, and higher counts for bacteria in the Selenomonadales order of the Firmicutes phylum. The Cod group showed greater 
similarity to the Salmon group than to the Control group. Intake of fibres, proteins, fats and carbohydrates, faecal daily mass 
and output of fat, cholesterol and total bile acids, and serum concentrations of cholesterol, triacylglycerols, non-esterified 
fatty acids and total bile acids were not altered in the experimental groups.
Conclusion A high intake of cod or salmon fillet modulated gut microbiota but did not affect faecal output or serum con-
centrations of lipids and total bile acids.
Clinical trial registration This trial was registered at clinicaltrials.gov as NCT02350595.
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Introduction
Gut microbiota may affect human nutrition and health by 
actively contributing to food digestion, energy harvesting 
and production of metabolic active compounds including 
short chain fatty acids and bile acids, but a definition of 
healthy human gut microbiome is still lacking [1]. The 
breakdown of proteins from the diet, followed by absorp-
tion of small peptides or free amino acids in the small 
intestine, is an efficient process in healthy adults; how-
ever even easily digestible proteins such as egg proteins 
escape digestion and absorption in the small intestine and 
may serve as substrate for microbial energy metabolism in 
the colon to produce mainly short chain fatty acids [2, 3]. 
Also dietary fibres, some starch and very small quantities 
of simple sugars enter the colon for fermentation to short 
chain fatty acids by bacteria [2].
The short chain fatty acids acetate, propionate and 
butyrate are generally accepted to be beneficial for the gut 
function and morphology [4], and improve glycaemic con-
trol and reduce appetite in addition to serve as an energy 
source for the host [5]. Gut microbiota also plays impor-
tant roles in the microbial deconjugation and dehydroxyla-
tion of bile acids and in the enterohepatic circulation of 
bile acids, and may directly regulate circulating choles-
terol concentration [6, 7]. Glycine or taurine conjugated 
bile acids produced from cholesterol in the liver is decon-
jugated to secondary bile salts by bile salt hydrolases, 
found in all major bacterial divisions, before reabsorption 
as a part of the enterohepatic cycle [6, 7]. Thus, changes 
in diets can be expected to affect the gut microbiota and 
through changes in physiological processes this may affect 
health and development of diseases.
Clinical studies have shown that fish intake or fish pro-
tein supplementation is associated with increased HDL-
cholesterol and/or lower LDL-cholesterol concentrations 
[8–13]. Lower circulating cholesterol concentration is also 
found in rats fed fish or fish proteins [14–20], and it has 
been suggested that this may in part be regulated through 
a higher faecal bile acid excretion [14, 19–21]. A reduction 
in circulating cholesterol concentration through increased 
faecal bile acid output may therefore be associated with 
changes in gut microbiota composition.
The information on the effect of diets on gut microbiota 
composition and function in humans is scarce. Short-term 
effects on the microbial community structure have been 
reported in healthy adults after intake of plant- or animal-
based diets, or high-fat/low-fibre or low-fat/high-fibre diets 
[22, 23], and non-digestible carbohydrates (dietary fibres) 
beneficially affect gut function and affects gut microbiota 
[24]. The effects of intake of protein-rich foods such as 
fish on gut microbiota composition and function are still 
little investigated. A 4-week crossover study with 2235 g 
of lean seafood per week showed only marginal effects on 
gut microbiome composition [25], and also supplementa-
tion with an n-3 PUFA preparation with high EPA content 
(2–10 g/day) for 12 weeks in healthy humans had little 
effect on intestinal bacteria [26]. When fed to rats, proteins 
from fish affected the composition of gut bacteria in the 
caecum differently from proteins from beef, pork, casein or 
soy, resulting in higher abundance of Firmicutes and less 
Bacteroidetes [27]. Fish may also affect gut microbiota 
due to its content of trimethylamine N-oxide (TMAO), 
found in various fish species including Atlantic salmon 
and Atlantic cod [28]. TMAO may reduce bile acid pro-
duction from cholesterol in liver [29], and evidence sug-
gests that changes in bile acid pool size can affect the gut 
microbiome community structure [30].
In a previous paper, we showed that a high intake of 
Atlantic salmon (750 g/week) for 8 weeks improved post-
prandial glucose regulation in study participants with over-
weight/obesity, whereas high intake of Atlantic cod (750 g/
week) did not affect glucose regulation in this study set-
ting [31]. The TMAO content is higher in cod compared 
to salmon [28], and we recently demonstrated that high 
cod intake, but not high salmon intake, markedly increased 
the TMAO concentration in serum and urine of this study 
population as a result of high TMAO intake from cod fillet 
[28]. In the present study, we aimed to further explore the 
biological materials from this randomised clinical trial to 
investigate if a high intake of cod or salmon would affect 
gut microbiota composition, faecal output and serum con-
centrations of lipids and bile acids. Little is known about 
the effects of high intake of cod or salmon on gut micro-
biota composition, and whether this could be linked to lipid 
homeostasis. Our hypothesis was that high intake of cod 
or salmon would affect gut microbiota and faecal output of 
lipids and bile acids, and thus improve circulating lipid sta-
tus in a group of adults with overweight/obesity.
Methods
Participants, study setting and ethics
The study design, the description of study participants, 
the study setting and the protocol for study visits have 
been published in detail previously [31]. In brief, the study 
population consisted of adults with overweight or obe-
sity, and all participants were of Norwegian ethnic origin 
(Caucasian) living in the Bergen area in South-Western 
Norway. Inclusion criteria were: BMI ≥ 27 kg/m2, fast-
ing blood glucose ≤ 7.0  mmol/l and age 18–69  years. 
Exclusion criteria were high habitual fish/seafood intake 
(> 500  g/week), pregnancy, incompatibility with fish 
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consumption (allergies, intolerance and/or dislike), diag-
nosed diabetes mellitus, heart disease or gastrointestinal 
diseases, use of medications affecting lipid metabolism or 
glucose homoeostasis, use of anti-inflammatory medica-
tions, use of supplements containing n-3 PUFAs, inten-
tional weight loss and large fluctuation in body weight 
(> 3 kg) over the previous 2 months. Participants were 
interviewed about their fish/seafood intake before they 
were included in the study, and those with a regular fish 
intake > 1 fish dinner per week were instructed to avoid 
eating fish for 4 weeks before the baseline visit. Very few 
participants (< 10%) had an intake above 1 fish dinner per 
week before enrolment to the study and went through a 
4-week fish-free period, and those with a habitual fish/sea-
food intake > 500 g/week were not included in the study.
The study was designed as a randomised, controlled 
intervention study with a parallel group design, with three 
intervention arms: Atlantic cod (wild-caught Gadus morhua) 
in weekly doses of 750 g, Atlantic salmon (farmed Salmo 
salar) in weekly doses of 750 g, and no-fish intake as the 
Control group. The intervention period was 8 weeks. In total, 
76 participants were included in the study and were ran-
domly assigned to the Cod group (N = 27), the Salmon group 
(N = 27) or the Control group (N = 22). The participants were 
randomised into the different groups by the project man-
ager by drawing lots, and the participants were informed 
about their group allocation during the baseline visit. All 
examinations were conducted at the Clinical Research Unit 
at the Haukeland University Hospital, Bergen, Norway. To 
enhance compliance, the participants were contacted by 
phone approximately 1 week prior to baseline and end point 
visits, during which they were informed of the schedule and 
procedures for the following visit. Also, a text message was 
sent 1–3 days before the 8-week visit, as a reminder of how 
to prepare for the upcoming visit. For any inquires during 
the trial period, members of the research group could be 
reached by email or telephone. Compliance was monitored 
through interviews; after 1, 4 and 8 weeks intervention, the 
participants in the fish-eating groups were asked how many 
dinners with cod/salmon they had not eaten since the last 
contact, instead of asking how well they had complied, to 
lower the bar for reporting missing intake. Participants in the 
Control group were interviewed about their intake of fish/
seafood after 1, 4 and 8 weeks. Noncompliance was defined 
as not following the protocol with regard to fish intake (omit-
ting more than 3 fish dinners in the fish-eating groups), other 
dietary changes or use of prescription medicine not compat-
ible with the inclusion criteria, or changes in physical activ-
ity. As reward for completing the study, participants were 
offered a dietary consultation with a student dietician and 
all results from blood analyses.
The study was conducted according to the guidelines laid 
down in the Declaration of Helsinki, and all procedures were 
approved by the Regional Committee for Medical and Health 
Research Ethics of Western Norway (REC no.: 2011/572). 
Written informed consent was obtained from all subjects.
Health professionals performing blood sampling, and per-
sonnel conducting the laboratory analyses, were all blinded 
to participants’ identity and group allocation. All data were 
analysed anonymously. This trial was registered at clinical-
trials.gov as NCT02350595.
Interventions
Cod and salmon fillets were provided to the participants as 
frozen skin- and boneless fillet portions (mean weight with 
standard deviation; 150 (SD 10) g; Lerøy Seafood Group 
ASA), and pallets of fish were chosen at random from 
Lerøy’s warehouse in Bergen, Norway. The cod and salmon 
fillets were supplied free of charge to the participants, and 
were distributed at the baseline visit or at any time during 
the study period, if preferred. Participants in the Cod group 
were instructed to eat five dinners per week containing 150 g 
of cod fillet, and participants in the Salmon group were 
instructed to eat five dinners per week containing 150 g of 
salmon fillet. The participants in the fish-eating groups were 
instructed not to exceed a total amount of 750 g of fish/week, 
not to consume any other types of fish or seafood during the 
study period, and to otherwise maintain their normal eat-
ing habits throughout the study period apart from eating the 
mandatory amount of 750 g fish/week. The Control group 
was also instructed to continue their normal eating habits, 
except to avoid fish and seafood intake. Participants in both 
fish intervention groups received a booklet with recipes for 
inspiration and to help them to increase the variation of their 
meals, as previously described [13]. The participants in the 
Control group did not receive any recipes, to avoid them 
being inspired to change their dietary habits during the study 
period.
Subjects in all groups were instructed not to change 
their physical activity level during the intervention period. 
The participants’ dietary intake and habitual lifestyle were 
recorded at the baseline and the end point visits, using food 
record charts and a questionnaire for reporting physical 
activity. The participants were asked about the types of phys-
ical activity they engaged in, such as whether they worked 
out in a gym, were members of sports clubs or whether they 
worked out individually, the type of physical activity (e.g. 
hiking, running, biking) and the number of hours of light 
physical activity (not sweaty/not breathless) or hard physical 
activity (with sweat/breathless). The participants completed 
the questionnaire at the baseline and end point visits. The 
weekly number of hours and the intensities of the physi-
cal activities were coded as continuous variables. Reported 
energy and macronutrient intake and physical activity were 
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similar between the groups at baseline and did not change 
within the groups during the study period [31].
Protocol for study visits
The total study period was 8 weeks, with baseline visits 
between August 22, 2011 and September 19, 2011. Exami-
nations were conducted in the morning after an overnight 
fast. The participants were instructed not to eat or drink 
anything except water, and not to use substances containing 
nicotine after 22.00 h the previous day, and to avoid physical 
exercise and alcohol for 24 h before each visit.
Body height was measured at the baseline, using a wall-
mounted stadiometer (Seca 222; Seca). Body weight and 
body composition were measured in a fasted state using a 
bioelectrical impedance analysis device (InBody 720; Bio-
space Co. Ltd) at the baseline and the end point visits.
Fasting blood samples and morning urine were collected 
at baseline and end point. Blood was drawn into BD Vacu-
tainer SST II Advance gel tubes (Becton, Dickinson and 
Company) for isolation of serum and in Vacuette K2EDTA 
tubes (Greiner Bio-one, Austria) for collection of whole 
blood. The staff complied with a strict protocol for pre-
analytical sample handling to ensure high sample quality. 
Serum, whole blood and urine were aliquoted and frozen at 
− 80 °C until analyses.
Estimation of dietary intakes
Participants completed dietary records of the five preceding 
days before the baseline visit and the 8-week visit, includ-
ing at least 1 weekend day. The intakes of non-digestible 
dietary fibre, starch, total fat, cholesterol and protein were 
calculated from the participants’ dietary records using the 
‘Mat på Data 5.1’ software [32], which contains informa-
tion on the nutrient contents in food items sold in Norway. 
In this database, dietary fibres are defined as non-digestible 
carbohydrates, and the collective term carbohydrate is used 
for available carbohydrates, i.e. including sugars and starch 
but not dietary fibres. Food records were checked for com-
pleteness at both study visits.
Faeces collection and analysis
Fifteen subjects from each experimental group were 
selected by the project manager (by drawing lots) to do a 
72-h faeces collection at baseline and end point, and the 
participants were informed about this during the baseline 
visit. Participants were interviewed about their opportu-
nity to store faeces in their home freezer before receiv-
ing equipment for collection of faeces. The participants 
received detailed written and verbal instructions on how 
to conduct a 72-h faeces collection and were provided with 
appropriate plastic containers with tight lids (1 l) and a 
holder to support the containers in the toilet. Faeces were 
collected on three subsequent days, and participants in the 
fish groups were instructed to complete the baseline faeces 
collection before they started consuming cod or salmon.
The participants were instructed to store the samples 
immediately after each bowel movement in a new con-
tainer in their own freezer, and they could deliver the 
faeces samples to our laboratory at any time throughout 
the intervention period. The faecal samples were stored at 
− 20 °C until further processing. The faeces were weighed 
in day by day and the total faeces from 72 h collection for 
each participant at each time point were pooled, mixed 
with twice the amount of water, homogenised with a T 50 
basic ULTRA-TURRAX® (IKA® Werke, Staufen, Ger-
many) and stored at − 20 °C. Aliquots of faecal samples 
were weighed before and after freeze drying and the dry 
mass content of the stool samples was calculated.
Gut microbiota profile analysis was performed using 
the GA-map® Dysbiosis Test (Genetic Analysis AS, Oslo, 
Norway) by algorithmically assessing faecal bacterial 
abundance [33]. Briefly, the test is based on mechanical 
and chemical bacterial cell disruption and automated total 
bacterial genomic DNA extraction using magnetic beads, 
followed by PCR amplification of the 16S rRNA gene. 54 
DNA bacterial markers targeting more than 300 bacte-
ria based on their 16S rRNA sequence in seven variable 
regions (V3–V9) were analysed; 28 bacteria probes are 
species specific, 18 detect bacteria at genus level and 8 
probes detect bacteria at higher taxonomic levels. Probes 
are listed in Supplemental Table 1. Probe labelling is by 
single nucleotide extension and hybridisation to comple-
mentary probes coupled to magnetic beads, and signal 
detection by using BioCode 1000A 128-Plex Analyzer 
(Applied Bio-Code, Santa Fe Springs, CA, USA).
Cholesterol was measured in lipid extracts from fae-
ces as previously described [34, 35] using the Cholesterol 
Gen.2 kit for Cobas c111 from Roche Diagnostics GmbH 
(Mannheim, Germany). Total bile acids (3α-hydroxy bile 
acids) concentration was measured in freeze-dried fae-
ces after solid phase extraction with Chromabond C18 
ec (3 ml/200 mg, Macherey–Nagel, Düren, Germany) as 
described by Suckling et al. [36] and quantification using 
the enzymatic bile acid assay from Diazyme Laboratories, 
Inc. on the Cobas c111 system (Roche).
Faecal fatty acids were quantified using a modified van 
de Kamer method, described in detail elsewhere [37, 38]. 
In brief, acylglycerols and cholesterol esters were hydro-
lysed by boiling homogenised faecal samples with KOH 
and ethanol, before acidifying with HCl. Free fatty acids 
were extracted from the mixture using petroleum ether, 
and the molar amount of fatty acids was determined by 
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titration against 0.1 N NaOH using thymol blue as an 
indicator.
Analyses of serum, whole blood and urine samples
Analyses of total cholesterol, HDL-cholesterol, LDL-cho-
lesterol, triacylglycerol, total bile acids, glucose, C-reactive 
protein (CRP) and alanine transaminase (ALT) in blood 
serum were performed by routine methods at the Laboratory 
of Clinical Biochemistry at Haukeland University Hospi-
tal. Serum NEFA was analysed with the Cobas c111 system 
(Roche Diagnostics GmbH, Marburg, Germany) using the 
NEFA FS kit (DiaSys; Diagnostic Systems GmbH). Urine 
creatinine and HbA1c in whole blood were analysed on 
the Cobas c 111 system using the CREP2 (Creatinine plus 
ver.2) kit and the A1C-3 kit with A1CD2 haemolysing rea-
gent (Roche Diagnostics GmbH) for Cobas c111. Trimeth-
ylamine N-oxide (TMAO) and 1-methylhistidine (1-MeHis, 
π-methylhistidine) were measured in serum and urine at 
Bevital AS (Bergen, Norway, https ://www.bevit al.no) using 
liquid chromatography combined with tandem mass spec-
trometry, as previously described [39] by adding ion pairs 
for the analytes and isotope-labelled internal standards to 
the existing assay.
Outcome measurements
The primary outcome of the present study was the gut 
microbiota profile after a weekly intake of 750 g fillet from 
either cod or salmon, or a fish-free diet for 8 weeks. Sec-
ondary outcomes were changes in faecal output and serum 
concentrations of lipids and bile acids after cod or salmon 
intake, and possible correlations between markers of cod and 
salmon intake and gut microbiota.
Sample size estimation
The sample size calculation for this trial was originally con-
ducted with the aim of investigating the effects of high intake 
of cod or salmon on postprandial glucose regulation after a 
standardised breakfast in participants with overweight or 
obesity [31]. We estimated that it was necessary to include 
76 participants divided into three groups to ensure that 20 
participants in each group completed the trial with satisfac-
tory compliance, with a power of 80% and α of 0.05, and 
of these, 65 participants were included in statistical analy-
ses [31]. In the present study, we wanted to further explore 
the biological materials from this randomised clinical trial 
to investigate the effects of a high intake of cod or salmon 
on gut microbiota composition, faecal output of lipids and 
bile acids, and circulating lipids. The primary aim of the 
present study was to investigate the effects of high intake 
of cod or salmon on gut microbiota. Forty-five participants 
(15 participants in each experimental group) were selected 
for collection of all faeces produced in 72 h at baseline and 
end point, and of these three participants withdrew from 
the study, four participants were not able to complete their 
collection of faeces, and one participant was excluded from 
analysis due to poor compliance; thus, a total of 37 sets of 
faeces samples were collected for gravimetric and biochemi-
cal analyses. We were able to obtain complete microbiota 
profiles from faeces sampled at both baseline and end point 
from 33 participants.
This is the first study to investigate the effects of 8 weeks 
of high intake (750 g/week) of cod or salmon on gut micro-
biota and faecal output in adults with overweight/obesity; 
therefore, no data were available for sample size calculation 
for the present study.
Statistical analyses
Subjects who did not complete the study were excluded from 
the statistical analyses. For lipids and bile acids in faeces and 
serum, and for estimated intake of nutrients from dietary 
records, most data were not normally distributed according 
to the Shapiro–Wilk test, and nonparametric tests were used 
to investigate changes within groups (the Wilcoxon-signed 
ranks test). For these nonparametric data, the Kruskal–Wal-
lis test was used to compare values between the three groups 
at baseline. Changes within the groups were compared using 
univariate analysis of covariance (ANCOVA) with adjust-
ment for baseline values after log transformation. Data are 
expressed as medians and 25th, 75th percentiles. Categorical 
data were compared using the Pearson’s χ2 test. All com-
parisons were two-sided. Correlations between parameters 
were tested using two-tailed Spearman’s correlations test. 
Statistical analyses were conducted using SPSS Statistics 
25 (SPSS, Inc., IBM Company) and P < 0.05 was consid-
ered statistically significant. Patterns of microbiota profiles 
were investigated by performing principal component analy-
sis (PCA) on matrixes containing centred and standardised 
concentrations using SigmaPlot 14.0 (Systat Software, Inc.).
Results
Participant characteristics
Seventy-six participants were included in the study and com-
pleted the first study visit, and 68 participants completed 
the trial. Two participants (one woman in the Cod group 
and one man in the Salmon group) were excluded from 
analysis because they did not comply with the protocol, and 
one woman in the Salmon group was excluded from statis-
tical analysis after analyses of postprandial blood glucose 
revealed that she had prediabetes. In total, 65 subjects (29 
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men and 36 women) were included in the statistical analyses. 
The flow of participants in the study is presented in Fig. 1. 
The groups were similar at baseline in regard to sex distri-
bution, age, BMI, percentage body fat, percentage muscle 
mass, reported light (not sweaty/not breathless) and hard 
(with sweat/breathless) physical activity, and fasting serum 
concentrations of glucose, CRP and ALT (Table 1), with 
median age 45.5 (25th, 75th percentiles 36.2, 53.2) years and 
median BMI 32.3 (25th, 75th percentiles 29.6, 35.7) kg/m2. 
After 8 weeks, no changes were seen in any of the groups 
for BMI, percentage body fat or muscle mass (data not pre-
sented). None of the participants reported using antibiotics, 
probiotics or prebiotics at baseline or end point, or at any 
time during the intervention period. 
Fifteen participants from each of the experimental groups 
were chosen for collection of two periods of faeces for 72 h 
at baseline and at the end of the intervention period. Of these 
45 participants, 3 withdrew from the study (1 man and 1 
woman in the Cod group, 1 woman in the Control group) and 
4 men (2 in the Cod group and 2 in the Control group) were 
not able to complete their collection of faeces. One woman 
in the Cod group was excluded from analysis due to poor 
compliance. Table 2 presents the baseline characteristics for 
the 37 participants collecting faeces.
Estimated dietary intakes and calculated faecal 
output
The food intake was registered by participants for 5 days 
before the baseline and end point visits. We have previously 
shown that there was no difference in estimated energy 









34 men, 42 women
Cod group Salmon group Control group
27 participants
12 men, 15 women
Selected for faeces collection:
8 men, 7 women
27 participants
11 men, 16 women
Selected for faeces collection:
5 men, 10 women
22 participants
11 men, 11 women
Selected for faeces collection:
8 men, 7 women
23 participants:
10 men, 13 women
Faeces subgroup:
5 men, 6 women
25 participants
10 men, 15 women
Faeces subgroup:
5 men, 10 women
20 participants
10 men, 10 women
Faeces subgroup:
6 men, 6 women
22 participants
10 men, 12 women
Faeces subgroup:
5 men, 5 women
23 participants
9 men, 14 women
Faeces subgroup:
5 men, 10 women
20 participants
10 men, 10 women
Faeces subgroup:
6 men, 6 women
Drop-outs: 4*
Failed to collect 
faeces: 2 
Drop-outs: 2
Failed to collect 
faeces: 0 
Drop-outs: 2†











Fig. 1  Study overview of participants. Participants not complying 
with the protocol were not included in the statistical analyses. Non-
compliance was defined as not following the protocol in regard to fish 
intake (omitting more than 3 fish dinners in the fish-eating groups), 
other dietary changes or use of prescription medicine not compatible 
with the inclusion criteria, or changes in physical activity. *Of these, 
two participants (one man and one woman) in the Cod group were 
selected for faeces collection. †Of these, one participant (a woman) 
in the Control group was selected for faeces collection. ‡Of these, one 
participant (a woman) selected for faeces collection in the Cod group 
was excluded from analysis
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[31]. Here, we show that the estimated median intakes of 
non-digestible dietary fibre, starch, total fat, protein, cho-
lesterol and carbohydrates were not different between the 
experimental groups at baseline (Table 3). The estimated 
daily intake of non-digestible dietary fibres, starch, protein, 
cholesterol and carbohydrates were not changed from base-
line to end point. The estimated daily total fat intake was sig-
nificantly increased in the Control group (15 of the 20 par-
ticipants showed increased fat intake), but this change was 
not significantly different when compared to the Cod group 
and the Salmon group. The combined intake of the macronu-
trients fat, protein and carbohydrates was not changed within 
any of the group or between the groups (p ANCOVA for 
group comparisons was 0.29, data not presented).
In the subgroups of participants that collected all faeces 
produced for 72 h before the baseline and end point visits, 
the median daily total faeces wet weight, dry weight, cho-
lesterol, total fat (measured as fatty acids) or total bile acids 
outputs were not different between the groups at baseline 
and did not change from baseline to end point within any of 
the groups (Table 4).
Gut microbiota
The signals for 54 gut microbiota DNA probes in total 
72 h faeces collected at baseline and at end point were 
compared for 33 participants (N = 9 in Cod group, N = 13 
in Salmon group and N = 11 in Control group) using PCA. 
For the baseline analyses, the PCA score plot revealed no 
Table 1  Participant 
characteristics at baseline: 
overview of all participants 
that completed the study and 
were included in the statistical 
analysis
Medians and 25th and 75th percentiles
CRP C-reactive protein, ALT alanine transaminase
* Groups were compared at the baseline using the Pearson’s χ2 (categorical data) or the Kruskal–Wallis test 
(continuous data). Glucose, CRP and ALT were measured in serum collected in a fasting state





Men/women 10/12 9/14 10/10 0.77
Age, years 47.2 38.0, 54.2 45.9 43.1, 52.2 39.8 31.1, 52.7 0.39
BMI, kg/m2 31.0 29.2, 35.9 31.9 29.9, 34.6 34.4 29.3, 36.5 0.64
Body fat, % 39.3 28.3, 42.9 39.9 30.0, 42.9 39.1 32.5, 41.0 0.99
Muscle mass, % 34.4 32.5, 41.4 33.3 31.5, 40.0 34.0 32.4, 38.5 0.85
Light physical activity, h/week 1 0, 4 2 2, 3 2 1, 3 0.35
Hard physical activity, h/week 2 0, 3 2 1, 2 2 0, 3 0.97
Glucose, mmol/l 5.2 4.9, 5.6 5.2 4.9, 5.5 5.3 4.8, 5.6 0.96
CRP, mg/l 2.0 0.78, 3.25 2.0 0.9, 3.0 2.5 2.0, 5.8 0.084
ALT, U/l 27 20, 43 26 17, 39 28 16, 36 0.56
Table 2  Participant 
characteristics at baseline: 
overview of participants that 
collected faeces
Medians and 25th and 75th percentiles
CRP C-reactive protein, ALT alanine transaminase
* Groups were compared at the baseline using the Pearson’s χ2 (categorical data) or the Kruskal–Wallis test 
(continuous data). Glucose, CRP and ALT were measured in serum collected in a fasting state





Men/women 5/5 10/5 6/6 0.58
Age, years 49.4 36.6, 54.5 46.4 43.2, 53.9 39.8 31.1, 52.7 0.28
BMI, kg/m2 30.4 28.8, 36.7 31.5 29.5, 34.6 33.3 29.1, 36.2 0.90
Body fat, % 37.9 28.2, 40.8 39.9 30.0, 42.2 39.1 33.0, 40.1 0.84
Muscle mass, % 34.6 32.6, 40.7 33.3 31.8, 40.0 34.0 33.2, 37.9 0.81
Light physical activity, h/week 1 1, 3 2 1, 3 2 1, 3 0.81
Hard physical activity, h/week 2 0, 4 2 1, 2 2 0, 3 0.80
Glucose, mmol/l 5.2 4.9, 5.6 5.3 5.1, 5.6 5.2 4.7, 5.8 0.75
CRP, mg/l 2.0 0.9, 4.3 2.0 0.9, 3.0 4.0 2.0, 9.8 0.23
ALT, U/l 25 20, 44 25 17, 32 23 15, 34 0.56
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separation between the dietary groups by the two first princi-
pal components (PC1 explained 26.22% and PC2 explained 
9.82% of the variation in the dataset, Fig. 2a). The loading 
plot showed no clear grouping of the bacteria at baseline 
(Fig. 2b). The PCA showed no relation of the microbiota 
profile with participants’ age, sex, BMI, percent body fat, 
percent muscle mass, dietary intake (fibre, starch, fat, pro-
tein, carbohydrates, cholesterol), serum lipids or NEFA, 
serum CRP, whole blood HbA1c, stool content of dry mass 
and moisture, and daily faecal output of fat, cholesterol and 
total bile acids at baseline (data not presented).
In the PCA for end point data, the participants showed a 
propensity to cluster according to their experimental group 
affiliation (PC1 and PC2 explained 25.67 and 10.11%, 
respectively, of the variation in the dataset, Fig. 3a). The 
Salmon group was almost completely separated from the 
Control group, whereas the Cod group showed greater 
similarity to the Salmon group than to the Control group. 
The loading plot revealed that the separation was in part 
due to a trend of lower counts for bacteria that belong to 
the Bacteroidales order in the Bacteroidetes phylum and 
the Clostridiales order of the Firmicutes phyla, and higher 
counts for a few bacteria in the Firmicutes phylum includ-
ing the Selenomonadales order in the Cod and Salmon 
groups when compared to the Control group (Fig. 3b).
Serum lipids
Serum concentrations of total cholesterol, LDL-choles-
terol, triacylglycerol, NEFA and total bile acids were 
not changed from baseline to end point within any of 
the experimental groups, and no differences were seen 
Table 3  Estimated daily dietary 
intake of dietary fibre, starch, 
fat, protein, cholesterol and 
carbohydrates based on 5 days 
dietary records at baseline and 
after 8 weeks*
Medians and 25th and 75th percentiles
* No differences were seen between the groups at the baseline (Kruskal–Wallis test). Results are presented 
for 22 participants in the Cod group, 23 participants in the Salmon group and 20 participants in the Control 
group
† Within-group changes are tested using the Wilcoxon’s signed-ranks test
‡ Changes within Cod group, Salmon group and Control group are compared using analysis of covariance 
(ANCOVA) with adjustment for baseline values after log transformation
Baseline 8 weeks P† P‡
Median 25th, 75th percentile Median 25th, 75th percentile
Non-digestible dietary fibre (g/day)
 Cod group 20.0 16.2,24.5 20.6 17.4,27.3 0.43 0.67
 Salmon group 18.7 15.5,21.8 18.8 16.3,23.5 0.78
 Control group 17.9 13.8,20.9 17.7 13.8,25.2 0.31
Starch (g/day)
 Cod group 115 82,141 107 88,136 0.78 0.81
 Salmon group 114 93,143 96 80,133 0.41
 Control group 133 99,168 102 95,143 0.21
Fat (g/day)
 Cod group 90 68,115 83 66,108 0.45 0.096
 Salmon group 94 64,120 93 84,120 0.14
 Control group 91 74,113 91 81,126 0.036
Protein (g/day)
 Cod group 94 84,122 100 74,114 0.86 0.88
 Salmon group 86 77,104 92 83,98 0.85
 Control group 92 80,106 91 72,122 0.83
Cholesterol (mg/day)
 Cod group 411 260,491 400 305,516 0.88 0.79
 Salmon group 372 287,602 367 324,474 0.47
 Control group 308 207,438 363 223,502 0.30
Carbohydrates (g/day)
 Cod group 203 168,248 181 162,225 0.18 0.49
 Salmon group 197 167,231 188 144,233 0.74
 Control group 209 164,272 195 141,281 0.90
European Journal of Nutrition 
1 3
Table 4  Faecal output at 
baseline and after 8 weeks*
Medians and 25th and 75th percentiles
* No differences were seen between the groups at the baseline (Kruskal–Wallis test). Results are presented 
for 10 participants in the Cod group, 15 participants in the Salmon group and 12 participants in the control 
group
† Within-group changes are tested using the Wilcoxon’s signed-ranks test
‡ Changes within the Cod group, Salmon group and Control group are compared using the analysis of 
covariance (ANCOVA) with adjustment for baseline values after log transformation
Baseline 8 weeks P† P‡
Median 25th, 75th percentile Median 25th, 75th percentile
Total wet weight of faeces, g/day
 Cod group 189 107,238 183 129,227 0.65 0.53
 Salmon group 133 80,228 131 68,190 0.61
 Control group 145 81,198 130 77,197 0.53
Total dry weight of faces, g/day
 Cod group 42 27,63 39 29,58 0.65 0.61
 Salmon group 34 16,51 27 23,30 0.12
 Control group 29 22,39 20 16,37 0.73
Cholesterol, µmol/day
 Cod group 829 532,1139 938 703,1255 0.65 0.56
 Salmon group 699 276,1592 524 258,941 0.14
 Control group 760 347,2201 538 253,1460 0.24
Total fatty acids, g/day
 Cod group 6.47 3.94,12.52 7.21 4.18,9.33 0.80 0.61
 Salmon group 5.63 3.40,8.22 5.88 3.49,9.48 0.31
 Control group 4.24 3.16,7.79 4.62 2.23,8.33 0.53
Total bile acids, µmol/day
 Cod group 199 183,208 205 188,209 0.14 0.63
 Salmon group 198 182,204 203 192,210 0.67




































Loadings PC1 (26.22 %)
A B
Fig. 2  Scores (a) and loadings (b) from the first two principal com-
ponents (PC1 and PC2) obtained from principal component analy-
sis using centred and standardised gut bacteria counts in faeces at 
baseline for N = 9 subjects in the Cod group, N = 13 subjects in the 
Salmon group, and N = 11 subjects in the Control group. The score 
plot (a) shows the experimental groups (blue diamond; Cod group, 
red squares; Salmon group, green triangles; Control group). The 
loading plot (b) show bacterial signals by phylum (open black cir-
cles; Actinobacteria, red squares, Bacteroidetes, orange circles; Fir-
micutes, blue diamond; Proteobacteria, green triangle; Verrucomicro-
bia)
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between the groups for changes over time (Table 5). Serum 
HDL-cholesterol was reduced after 8 weeks in the Control 
group, but this change was not significantly different when 
compared to the Cod group and the Salmon group.
Correlations between estimated dietary intakes, 
faecal outputs and serum lipid concentrations
The combined baseline and end point data sets were ana-
lysed using Spearman’s two-tailed correlation analysis 
(Table 6). The dietary intakes of fibre, starch, fat, proteins, 
cholesterol and carbohydrates were correlated with wet and 
dry faecal weight, with the strongest correlation between 
fibre intake and faecal dry weight (Spearman’s correlation 
0.418, p = 2.4 × 10–4). Faecal cholesterol output correlated 
with intakes of starch and carbohydrates, and faecal fat out-
put correlated with intakes of fibre, fat, proteins and cho-
lesterol, whereas total bile acid faecal output was not sig-
nificantly correlated to dietary intakes. Serum cholesterol, 
HDL-cholesterol, LDL-cholesterol, triacylglycerols and 
total bile acids concentrations were not correlated to faecal 
outputs, but serum NEFA concentration was inversely cor-
related to faecal wet and dry weights and faecal outputs of 
fat and total bile acids. The strongest associations for faecal 
outputs of total cholesterol and fat were seen for faecal wet 
and dry weights, with p < 10–8, however correlations were 
not statistically significant between faecal weights and faecal 
total bile acids output. The correlation between wet and dry 
daily faecal weights were 0.850 (p = 1.1 × 10–21).
Correlations between biomarkers of Cod 
and Salmon intake and gut microbiota
We recently found that serum and urine concentrations of 
TMAO and 1-MeHis were promising biomarkers of fish 
intake, as both serum and urine concentrations of TMAO and 
1-MeHis were significantly increased after cod and salmon 
intake, respectively, in samples from participants in the present 
study [28]. Here, we explored the correlations between these 
biomarkers and gut microbiota signals, and bacteria showing 
at least one statistically significant correlation are presented in 
Table 7. Serum and urine TMAO concentrations were posi-
tively correlated with the Akkermansia muciniphila signal at 
baseline, whereas these correlations were not siginficant at end 
point. Serum TMAO concentration was inversely correlated 
with Clostridium methylpentosum at baseline, but not at end 
point. Urine TMAO concentration was positively correlated 
with Bacteroides sp. at baseline and negatively correlated with 
Bacteroides sp. at end point, but only baseline urine TMAO 
concentration correlated with Proteobacteria.
Baseline serum concentration of 1-MeHis was positively 
correlated with Akkermansia muciniphila and Lachnosp Incer-
tae Sedis, Phascolarctobacterium faecium, whereas no cor-
relations with gut microbiota were seen for urine 1-MeHis 
at baseline. At end point, serum 1-MeHis was negatively 
correlated with Eubacterium rectale and urine 1-MeHis was 
negatively correlated with Coprobacillus cateniformis, Eubac-
terium rectale, Staphylococcus epidermidis and Streptococ-






































Loadings PC1 (25.67 %)
Fig. 3  Scores (a) and loadings (b) from the first two principal com-
ponents (PC1 and PC2) obtained from principal component analysis 
using centred and standardised gut bacteria counts in faeces at end 
point for N = 9 subjects in the Cod group, N = 13 subjects in the 
Salmon group, and N = 11 subjects in the Control group. The score 
plot (a) shows the experimental groups (blue diamond; Cod group, 
red squares; Salmon group encircled by a red ellipse, green trian-
gles; Control group encircled by a green ellipse). The loading plot (b) 
show bacterial signals by phylum (open black circles; Actinobacteria, 
red squares, Bacteroidetes, orange circles; Firmicutes, blue diamond; 
Proteobacteria, green triangle; Verrucomicrobia)
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Discussion
In the present study, we investigated the effects of high 
intake of cod or salmon on the gut microbiota profile. We 
observed that a weekly intake of 750 g of cod or salmon 
changed the microbiota composition, but did not change 
faecal output and serum concentrations of lipids and total 
bile acids.
Dietary proteins are substrates for microbial energy 
metabolism in the colon [2, 3] and may affect gut micro-
biota profile. Here, we show that high intake of cod or 
salmon resulted in a separation of bacteria by the PCA, with 
lower counts for bacteria in the Bacteroidetes phylum and 
the Clostridiales order of the Firmicutes phyla, and higher 
counts for bacteria in the Selenomonadales order in the 
Firmicutes phylum when compared to the Control group. 
The separation from Control group was almost complete 
for participants in the Salmon group, and less clear for those 
in the Cod group. Although the first two components from 
the PCA explained merely 35.78% of the variation in the 
dataset, this observed separation between the experimen-
tal groups are of potentially great interest. A higher abun-
dance of Bacteroidetes has been found in patients with type 
2 diabetes [40], and the present finding of lower counts of 
Bacteroidetes especially in the Salmon group fits nicely 
with our previous report of improved postprandial glucose 
regulation after high salmon intake [31]. Lower numbers of 
Bacteroides spp. have also been observed in fish fermenta-
tions compared to chicken in vitro for human faeces [41]. 
Similar findings have been reported for gut bacteria in the 
caecum in Sprague–Dawley rats fed fish as the sole pro-
tein source, with lower abundance of Bacteroidetes how-
ever with higher abundance of Firmicutes [27], whereas 
intake of lean seafood or n-3 PUFA supplementation did 
Table 5  Serum fasting 
concentrations of lipids, NEFA 
and total bile acids at baseline 
and after 8 weeks*
Medians and 25th and 75th percentiles
* No differences were seen between the groups at the baseline (Kruskal –Wallis test). Results are presented 
for 22 participants in the Cod group, 22 participants in the Salmon group and 19 participants in the control 
group. NEFA, non-esterified fatty acids
† Within-group changes are tested using the Wilcoxon’s signed-ranks test
‡ Changes within Cod group, Salmon group and Control group are compared using the analysis of covari-
ance (ANCOVA) with adjustment for baseline values after log transformation
Baseline 8 weeks P† P‡
Median 25th, 75th percentile Median 25th, 75th percentile
Serum total cholesterol, mmol/l
 Cod group 5.7 4.5,6.1 5.5 4.3,6.4 0.84 0.26
 Salmon group 5.0 4.4,5.5 4.8 4.2,5.4 0.10
 Control group 5.2 4.4,5.5 5.0 4.3,5.4 0.19
Serum HDL-cholesterol, mmol/l
 Cod group 1.3 1.0,1.5 1.3 0.9,1.5 0.59 0.21
 Salmon group 1.3 1.2,1.4 1.3 1.0,1.4 0.48
 Control group 1.3 1.1,1.6 1.2 1.0,1.5 0.0075
Serum LDL-cholesterol, mmol/l
 Cod group 3.5 2,6,4.5 3.6 2.6,4.4 0.30 0.39
 Salmon group 3.2 2.6,3.6 3.1 2.4,3.5 0.30
 Control group 3.4 2.5,3.6 3.2 2.5,3.5 0.97
Serum triacylglycerols, mmol/l
 Cod group 1.26 1.08,1.93 1.20 0.91,1.64 0.78 0.33
 Salmon group 0.98 0.76,1.45 1.00 0.73,1.53 0.76
 Control group 1.35 0.90,1.69 1.41 0.91,1.83 0.32
Serum NEFA, mmol/l
 Cod group 0.50 0.39,0.70 0.52 0.37,0.64 0.88 0.92
 Salmon group 0.51 0.43,0.71 0.48 0.37,0.56 0.38
 Control group 0.56 0.35,0.66 0.52 0.45,0.63 0.89
Serum total bile acids, µmol/l
 Cod group 1.0 0.7,2.3 1.5 0.5,2.0 0.81 0.41
 Salmon group 1.0 0.6,3.0 1.0 0.8,2.0 0.70
 Control group 1.0 0.8,3.0 2.5 1.0,3.0 0.42
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not affect gut microbiome composition [25, 26]. The dif-
ferences in gut microbiota profile between the experimental 
groups in the present study could be a consequence of the 
high intake of cod or salmon in the fish groups, but it may 
also be due to the higher intake of meat in the Control group 
where nearly 100% of dinners contained red or white meat 
as opposed to around only 29% of the dinners in the fish-
eating groups [28]. Since there is no consensus regarding 
what can be considered a healthy human gut microbiome 
[1], an interpretation of the present findings cannot be made 
beyond stating that high intake of cod or salmon has the 
capacity to alter the gut microbiome profile compared to a 
Control group consuming red or white meat.
The faecal microbiota richness and variance of bacteria 
is strongly influenced by stool moisture, which in turn is 
determined by transit time and residence time in the colon 
and rectum [1]. Fibre intake, especially non-digestible fibre, 
and physical activity are associated with shorter intestinal 
transit time and increased gastrointestinal motility, leading 
to a higher water content in the stool [42, 43]. Also total food 
intake, body weight and diets are important determinants 
for total stool mass [42]. The medians for measured daily 
faecal wet weight and outputs of dry mass, fat, cholesterol 
and total bile acids were within the normal ranges and indi-
cated healthy gastrointestinal function in our participants 
[42]. Non-digestible fibres undergo minimal changes in the 
digestive tract and have a high water holding capacity and 
thus increase faecal mass, but also digestible fibres can cause 
an increase in faecal weights since the presence of ferment-
able substrates will stimulate proliferation of bacteria and 
results in soft, bulky and water-retaining stools [42]. In line 
with this, the unchanged faecal wet and dry weights (from 
two 72 h faecal collection periods) during the course of the 
present trial corresponds well with the unaltered intake of 
dietary fibre and the unchanged levels of physical activity 
[31]. The significant correlation between estimated dietary 
fibre intake and measured faecal dry mass output (Spear-
man’s correlation 0.418, p = 2.4 × 10–4) suggests that both 
the registration of food intake and the collection and analy-
sis of faeces were successful. Since no changes were seen 
in wet and dry faecal mass within any of the experimental 
groups, we conclude that the differences in gut microbiota 
Table 7  Spearman’s 
correlations of serum and 
urine concentrations of 
trimethylamine N-oxide 
(TMAO) and 1-methylhistidine 
(1-MeHis) with gut microbiota 
combined for Cod group, 
Salmon group and Control 
group, showing only 
correlations where at least one 
bacterial probe is significantly 
correlated with TMAO or 
1-MeHis
* Correlation is significant at the 0.05 level (two-tailed)
** Correlation is significant at the 0.01 level (two-tailed)
Counts Serum (µmol/l) Urine (µmol/mmol creati-
nine)
TMAO 1-MeHis TMAO 1-MeHis
Baseline
 Akkermansia muciniphila 0.416* 0.366* 0.375* 0.084
 Bacteroides sp. 0.200 − 0.068 0.372* − 0.066
 Clostridium methylpentosum − 0.350* 0.096 − 0.073 0.218
 Coprobacillus_cateniformis 0.229 − 0.085 0.047 − 0.011
 Eubacterium rectale − 0.115 0.086 − 0.071 0.141
 Lachnosp Incertae Sedis − 0.186 0.382* − 0.127 0.331
 Mycoplasma hominis 0.253 0.100 0.298 0.232
 Phascolarctobacterium faecium 0.129 0.437* 0.212 0.222
 Proteobacteria 0.201 0.166 0.358* 0.064
 Staphylococcus epidermidis − 0.213 0.125 − 0.294 0.136
 Streptococcus agalactiae − 0.297 − 0.117 − 0.148 0.085
Endpoint
 Akkermansia muciniphila 0.306 − 0.022 − 0.142 − 0.106
 Bacteroides sp. − 0.128 0.103 − 0.417* − 0.087
 Clostridium methylpentosum 0.135 − 0.077 0.106 − 0.097
 Coprobacillus cateniformis − 0.025 − 0.079 − 0.163 − 0.415*
 Eubacterium rectale − 0.130 − 0.384* − 0.286 − 0.482**
 Lachnosp Incertae Sedis − 0.059 − 0.214 − 0.265 − 0.338
 Mycoplasma hominis 0.080 0.151 − 0.040 0.371*
 Phascolarctobacterium faecium 0.201 0.272 − 0.223 − 0.216
 Proteobacteria 0.089 − 0.062 0.126 0.034
 Staphylococcus epidermidis − 0.121 − 0.321 − 0.307 − 0.364*
 Streptococcus agalactiae − 0.233 − 0.310 − 0.282 − 0.513**
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profile between the groups were due to genuine differences 
in composition and were not a result of a ‘dilution effect’.
The role of faecal output in overweight and obesity is 
unclear, but the removal of excess energy by increased faecal 
excretion of lipids represents an attractive target and is the 
principle of weight loss drugs such as Orlistat. The faecal 
fat consists of undigested fat from dietary intake, bacteria 
and shredded epithelial cells [42], and the faecal fat excre-
tion in healthy persons is ≤ 7 g per day when the daily fat 
intake from the diet is between 50 and 150 g [44]. In the 
present study, the estimated median fat intake from food dia-
ries at baseline and end point was 90.5 (interquartile range 
72–114) g/day and the measured median faecal fat excretion 
for these time points was 5.5 (interquartile range 3.5–8.9) g/
day, and we found a weak but significant correlation between 
fat intake and faecal fat excretion (Spearman’s correlation 
0.294, p = 0.012). Diets that are rich in dietary fibres will 
increase the faecal output of fat by reducing the absorption 
capacity in the gut [42], and in line with this we found a 
strong correlation between dietary fibre intake and faecal 
fat output (Spearman’s correlation 0.431, p = 1.4 × 10–4). Fat 
contributed to a median 19% (interquartile range 14–23) of 
the faecal dry weight in the present study and these parame-
ters were strongly correlated (Spearman’s correlation 0.778, 
p = 3.6 × 10–16). Also exercise may affect gastrointestinal and 
gallbladder motility [43]; therefore, since the participants in 
this study were instructed to not change their eating habits 
except for the mandatory fish intake in the Cod group and 
the Salmon group and no-fish intake in the Control group, 
together with no change in the level of physical activity dur-
ing the intervention period [31], it is not surprising that we 
did not observe any changes in faecal fat excretion.
The circulating concentration of cholesterol is controlled 
by the rate of cholesterol biosynthesis regulated by HMG-
CoA reductase, by the uptake of LDL-particles facilitated 
by LDL-receptors and through faecal excretion of choles-
terol and bile acids. Bile formation is essential for total 
body cholesterol balance, as biliary excretion of cholesterol 
and conversion of cholesterol to bile acids are the principal 
routes of cholesterol excretion and catabolism, and the gut 
microbiota plays a key role in the enterohepatic circulation 
of bile acids [6, 7]. An increase in faecal bile acid excretion 
would enhance the biosynthesis of cholesterol and trigger 
an increased production of bile acids and up-regulate LDL-
receptors leading to lower circulating LDL-cholesterol con-
centrations. We recently investigated the effects of replacing 
25 wt% of casein in the regular AIN-93G diet [45] with cor-
responding amounts of proteins from cod or salmon fillets on 
cholesterol metabolism in obese Zucker fa/fa rats. Cod fillet 
feeding resulted in lower serum total, HDL- and LDL-cho-
lesterol concentrations and lower hepatic mRNA expressions 
of HMG-CoA reductase and LDL-receptor, without affect-
ing serum and faecal total bile acid concentration, faecal 
and liver cholesterol amounts in faeces, or liver cholesterol 
7 alpha-hydroxylase mRNA concentration in these rats [16]. 
These findings indicate that the lower circulating cholesterol 
concentration was not regulated through increased faecal 
output of cholesterol and/or bile acids, but was a result of 
lower endogenous production of cholesterol in rats fed cod 
fillet. Similar results were seen when obese Zucker fa/fa rats 
were fed salmon fillet as 25 wt% of the diet; serum concen-
trations of total, HDL- and LDL-cholesterol were lower in 
these rats compared to those fed the regular AIN-93G diet, 
with no effect on faecal excretion of cholesterol and total bile 
acids [17]. In contrast to our findings in rats, we observed 
no effects on serum cholesterol after high intake of cod or 
salmon in the present clinical trial. However, the observation 
that faecal outputs of cholesterol and total bile acids were 
not affected by high cod or salmon intake in our participants 
with obesity/overweight corresponded well with previous 
studies in rats fed cod or salmon fillet [16, 17].
TMAO concentrations in serum and urine are affected 
by gut microbiota production of trimethylamine from die-
tary precursors, dietary intake of TMAO and/or its precur-
sors, and kidney function [46, 47]. Participants in the pre-
sent study appeared to have normal kidney function since 
serum creatinine and urine albumin concentrations were 
within normal range both at start and the end of the inter-
vention period, and TMAO seems to be a good biomarker 
for cod intake in this study population with a significant 
increase in TMAO concentrations in serum and urine in this 
dietary group after 8 weeks intervention [28]. Trimethyl-
amine, the bacterial precursor for TMAO, is generated by 
gut microbiota through three pathways, either from choline, 
trimethylglycine (betaine), ergothioneine, dimethylglycine 
or carnitine, which are found in common foodstuffs such as 
seafood, terrestrial meat, egg, dairy products, vegetables, 
mushrooms, kidneys and liver; from dietary L-carnitine that 
may be converted to gamma-butyrobetaine [46]; or by reduc-
tion of TMAO by the gut microbiota (predominantly Entero-
bacteriaceae in the phyla Proteobacteria) [48]. Trimethyl-
amine is transported to the liver for oxidation to TMAO by 
flavin-containing monooxygenases [46]. Various bacterial 
phyla including Actinobacteria, Bacteroidetes, Firmicutes 
and Proteobacteria are associated with the first pathway 
(mentioned above) in the human colon [46], whereas espe-
cially Akkermansia muciniphila has been demonstrated to be 
associated with the carnitine–gamma-butyrobetaine–TMAO 
pathway [49]. In the present study, we found positive cor-
relations between serum and urine TMAO concentrations 
and the Akkermansia muciniphila signal (phylum: Verru-
comicrobia) at baseline, and correlations were also found 
between serum TMAO concentration and Clostridium meth-
ylpentosum (phylum: Firmicutes), and between urine TMAO 
concentration and Bacteroides sp. (phylum: Bacteroidetes) 
and unspecified bacteria of the phylum Proteobacteria. 
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Thus, TMAO may have been produced by either of the 
microbiota pathways for trimethylamine at baseline. The 
hepatic production of TMAO from gut microbiota-originat-
ing trimethylamine is small compared to the TMAO contri-
bution from fish intake [46]. Therefore, it is not surprising 
that the correlations between TMAO and gut bacteria for 
our study population were fewer (the only correlation was 
for urine TMAO concentration with Bacteroides sp.) after 
interventions with cod or salmon in two of the three experi-
mental groups, since TMAO predominately originated from 
fish intake and not microbial production.
1-MeHis, a potential biomarker for salmon intake [28], 
has not been described as a metabolite of or substrate for 
the gut microbiota. We have recently shown that serum 
and urine concentrations of 1-MeHis were significantly 
increased in the Salmon group in the present study [28]. 
1-MeHis from diet is not reutilised for protein synthesis or 
metabolised, and it is estimated that 90% of 1-MeHis from 
the diet is excreted in urine as 1-MeHis in humans [50]. At 
end point, urine concentration of 1-MeHis was negatively 
correlated with a few bacterial species, mainly in the Firmi-
cutes phylum, with the strongest negative correlations with 
Eubacterium rectale (class: Clostridia) and Streptococcus 
agalactiae (class: Bacilli), and with positive correlation with 
Mycoplasma hominis. Since little information is available 
regarding the consumption and production of 1-MeHis by 
gut microbiota, it is difficult to conclude if these correla-
tions are a result of changes in consumption or production 
of 1-MeHis by gut microbiota or simply non-causal associa-
tions. The described correlations between urine 1-MeHis 
concentration and gut microbiota correspond well with the 
results from PCA using end point data, thus urine 1-MeHis 
concentration may be a useful biomarker for salmon intake 
in future studies when interpreting the effects of diets on 
gut microbiota in humans, as an alternative or an addition to 
food diaries or food-frequency questionnaires.
We have recently shown that a high intake of salmon, but 
not of cod, for 4 weeks reduced triacylglycerol and increased 
HDL-cholesterol serum concentrations in healthy, normal 
weight adults [13]. This is in sharp contrast to findings in 
adults with overweight or obesity in the present study, where 
we found no effect of high cod or salmon intake on any 
of the measured serum lipid concentrations. This may be 
a consequence of larger heterogeneity in regard to factors 
such as age and percentage of body fat and muscle mass in 
the latter study.
The present study has some strengths and limitations. 
A strength is the use of 72 h faeces collection at baseline 
and end point, rather than using spot samples since the 
day to day variation in the faecal mass can vary widely 
for the same individual [1]. Also, faecal mass is affected 
by diet and physical activity [42], and gut microbiota is 
affected by medications including antibiotics [51] and 
metformin [52]. Our study participants did not change 
their diet except the mandatory intake of cod or salmon in 
the fish-eating groups or their physical activity, and none 
of the participants reported using antibiotics, probiotics, 
prebiotics or antidiabetics at baseline or end point, or at 
any time during the intervention period. Limitations for 
this study include shortcomings associated with the partic-
ipants’ faeces collection, such as failing to collect all pro-
duced stool over the 72 h periods and immediately deposit-
ing the filled containers in the freezer as instructed. The 
choice of analysing only 54 bacterial DNA probes using a 
method originally developed for identifying dysbiosis [33] 
can be criticised; still, the findings are of interest since 
the Salmon group and the Control group were partially 
separated by PCA. Complete gut bacteria characterisation 
should be conducted in future studies with similar design. 
The intakes of prebiotics such as polyphenols and inulin 
found in fruits, vegetables and berries may also affect gut 
microbiota [1, 53], but were not estimated in the present 
study. The sample size was relatively small, and a type II 
error may mask significant effects of the intervention in 
both gut microbiota and faecal output and serum concen-
trations of lipids and total bile acids due to low statistical 
power.
To conclude, despite the small sample size and the lim-
ited number of bacterial probes used, this study is unique 
since it demonstrates that a high intake of cod or salmon 
fillet may modulate gut microbiota in adults with over-
weight/obesity without known gastrointestinal disease. 
The high intake of cod or salmon did not affect faecal 
output or serum lipids and bile acids.
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